HitGen Hits China Drug Discovery Jackpot With MNC Tie-ups
Executive Summary
Wei Chen, head of R&D for Chengdu-based venture HitGen, talks to Scrip’s Brian Yang on how the Chinese startup is partnering with multinationals and is aiming to speed up new drug development in China through its own platform and a novel HDAC inhibitor for liver cancer.
You may also be interested in...
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.
Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m
WuXi Biologics and Harbin Gloria will get $18.5m up front for the Phase I asset GLS-010. Also, Cerecor divests depression drug to Janssen for up to $45m and Perrigo sells its API division for $110m in cash.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.